.png){kind=icon}
.png){kind=icon}
Return
Integrated meta-analysis and network pharmacology of Shenling Baizhu powder for type 2 diabetes
.png){kind=icon}
PRE
AI
C
D
L
G
DOI：10.1016/j.hermed.2025.101083.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Background: Shenling Baizhu powder (SLBZP), a traditional Chinese medicine formula, is increasingly employed for type 2 diabetes mellitus (T2DM), yet its efficacy and mechanisms of action are not fully elucidated. Objective: This study combines meta-analysis and network pharmacology to systematically evaluate the clinical efficacy and safety of SLBZP in T2DM and to elucidate its mechanisms of action. Methods: A comprehensive literature search was conducted up to July 2025. Meta-analysis was performed using RevMan, while network pharmacology identified active components, targets, and pathways. Molecular docking validated interactions between key compounds and targets. Results: Twenty-two randomised controlled trials (1900 patients) were included. Meta-analysis showed that SLBZP combined with western medicine significantly improved glucolipid metabolism and insulin resistance vs western medicine alone. Network pharmacology revealed Quercetin, Kaempferol, Licochalcone B, Medicarpin, and Isorhamnetin as key bioactive compounds acting on targets including PIK3CA, TP53, PIK3R1, STAT3, EGFR, PIK3CD, AKT1, CTNNB1, PRKACA, and MAPK1. Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment indicated involvement of Mitogen-activated protein kinase (MAPK) signalling, lipid metabolism, and atherosclerosis pathways. Conclusion: SLBZP exerts its clinical benefits in T2DM through pleiotropic mechanisms involving multiple components, targets, and pathways, likely mediated by a therapeutic synergy with Western medicine, which warrants further validation.
Keywords:
Shenling Baizhu powder
Type 2 diabetes mellitus
Systematic review
Meta-analysis
Network pharmacology
Journal
J
IF:
1.9
Papers:
45
Citations:
0
Organization
Cited Papers